 Ryan Fischer
Concepts (259)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 15 | 2023 | 47 | 5.640 |
Why?
| | Liver Diseases | 6 | 2023 | 18 | 2.420 |
Why?
| | Humans | 41 | 2024 | 6896 | 1.340 |
Why?
| | Immunosuppressive Agents | 6 | 2019 | 31 | 1.130 |
Why?
| | Male | 27 | 2024 | 3337 | 1.090 |
Why?
| | Sirolimus | 6 | 2019 | 8 | 1.070 |
Why?
| | Postoperative Complications | 4 | 2020 | 184 | 1.010 |
Why?
| | Child | 25 | 2024 | 3364 | 1.000 |
Why?
| | Fontan Procedure | 2 | 2021 | 19 | 0.910 |
Why?
| | Female | 23 | 2024 | 3525 | 0.890 |
Why?
| | Thrombosis | 1 | 2023 | 15 | 0.890 |
Why?
| | Dendritic Cells | 4 | 2011 | 6 | 0.880 |
Why?
| | Patient Compliance | 2 | 2020 | 55 | 0.750 |
Why?
| | Retrospective Studies | 15 | 2023 | 1296 | 0.750 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 9 | 0.740 |
Why?
| | Cryptosporidiosis | 1 | 2020 | 3 | 0.730 |
Why?
| | Immunocompromised Host | 1 | 2020 | 10 | 0.730 |
Why?
| | Esophageal Neoplasms | 1 | 2020 | 2 | 0.710 |
Why?
| | Scalp | 1 | 2020 | 2 | 0.710 |
Why?
| | Child, Preschool | 15 | 2024 | 1569 | 0.710 |
Why?
| | Head and Neck Neoplasms | 1 | 2020 | 2 | 0.710 |
Why?
| | Adenocarcinoma | 1 | 2020 | 9 | 0.710 |
Why?
| | Skin Neoplasms | 1 | 2020 | 11 | 0.710 |
Why?
| | Alagille Syndrome | 3 | 2024 | 3 | 0.690 |
Why?
| | Adolescent | 17 | 2024 | 2197 | 0.680 |
Why?
| | Neoplasms | 1 | 2021 | 128 | 0.670 |
Why?
| | Infant | 15 | 2023 | 1446 | 0.670 |
Why?
| | Anemia, Hemolytic, Congenital | 1 | 2019 | 3 | 0.670 |
Why?
| | Hydrops Fetalis | 1 | 2019 | 4 | 0.660 |
Why?
| | Electronic Health Records | 1 | 2019 | 64 | 0.660 |
Why?
| | Graft Rejection | 3 | 2020 | 31 | 0.610 |
Why?
| | Immune Tolerance | 3 | 2021 | 8 | 0.570 |
Why?
| | Intestines | 2 | 2013 | 29 | 0.560 |
Why?
| | Animals | 6 | 2021 | 729 | 0.500 |
Why?
| | Treatment Outcome | 11 | 2024 | 622 | 0.500 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2013 | 9 | 0.460 |
Why?
| | Intestinal Atresia | 1 | 2013 | 16 | 0.460 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2022 | 15 | 0.440 |
Why?
| | Adult | 8 | 2024 | 1181 | 0.420 |
Why?
| | Hypertension, Portal | 2 | 2022 | 7 | 0.410 |
Why?
| | Cholangitis, Sclerosing | 2 | 2023 | 2 | 0.410 |
Why?
| | Isoantigens | 2 | 2011 | 2 | 0.410 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2022 | 20 | 0.390 |
Why?
| | Myeloid Cells | 1 | 2011 | 1 | 0.390 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2011 | 11 | 0.390 |
Why?
| | Bone Marrow Transplantation | 1 | 2011 | 17 | 0.390 |
Why?
| | Hepatolenticular Degeneration | 1 | 2011 | 1 | 0.390 |
Why?
| | Heart Defects, Congenital | 2 | 2023 | 81 | 0.380 |
Why?
| | Cholestasis, Intrahepatic | 2 | 2021 | 3 | 0.360 |
Why?
| | Fatty Liver | 2 | 2013 | 4 | 0.360 |
Why?
| | Short Bowel Syndrome | 3 | 2015 | 4 | 0.360 |
Why?
| | Patient Participation | 2 | 2020 | 15 | 0.340 |
Why?
| | Muscular Dystrophy, Duchenne | 2 | 2019 | 2 | 0.330 |
Why?
| | Prospective Studies | 4 | 2023 | 525 | 0.320 |
Why?
| | Young Adult | 7 | 2024 | 647 | 0.280 |
Why?
| | Liver Failure | 2 | 2019 | 2 | 0.270 |
Why?
| | Liver Cirrhosis | 3 | 2023 | 10 | 0.260 |
Why?
| | Bile Acids and Salts | 2 | 2024 | 2 | 0.260 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2020 | 7 | 0.250 |
Why?
| | Forkhead Transcription Factors | 2 | 2020 | 6 | 0.250 |
Why?
| | Transition to Adult Care | 2 | 2022 | 19 | 0.250 |
Why?
| | Vancomycin | 2 | 2023 | 17 | 0.240 |
Why?
| | Pruritus | 1 | 2024 | 4 | 0.240 |
Why?
| | Comprehension | 1 | 2023 | 3 | 0.230 |
Why?
| | Middle Aged | 3 | 2021 | 608 | 0.230 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2023 | 5 | 0.230 |
Why?
| | Aspirin | 1 | 2023 | 5 | 0.230 |
Why?
| | Hepatic Artery | 1 | 2023 | 7 | 0.220 |
Why?
| | Anticoagulants | 1 | 2023 | 20 | 0.220 |
Why?
| | Vascular Diseases | 1 | 2023 | 8 | 0.220 |
Why?
| | Insurance | 1 | 2023 | 2 | 0.220 |
Why?
| | Intestine, Small | 2 | 2013 | 15 | 0.220 |
Why?
| | Cholestasis | 1 | 2022 | 2 | 0.210 |
Why?
| | Diagnosis, Differential | 2 | 2020 | 77 | 0.210 |
Why?
| | Digestive System Diseases | 1 | 2022 | 1 | 0.210 |
Why?
| | Gastroenterology | 1 | 2022 | 10 | 0.210 |
Why?
| | Heart Transplantation | 2 | 2020 | 14 | 0.200 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 13 | 0.200 |
Why?
| | Tumor Microenvironment | 1 | 2021 | 17 | 0.200 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2022 | 18 | 0.200 |
Why?
| | Cohort Studies | 2 | 2020 | 289 | 0.200 |
Why?
| | Adenosine Triphosphatases | 1 | 2021 | 3 | 0.200 |
Why?
| | T-Lymphocytes | 2 | 2013 | 31 | 0.200 |
Why?
| | Tacrolimus | 2 | 2019 | 10 | 0.190 |
Why?
| | Anti-Bacterial Agents | 2 | 2023 | 243 | 0.190 |
Why?
| | Biliary Tract Diseases | 1 | 2020 | 5 | 0.180 |
Why?
| | Diarrhea | 1 | 2020 | 18 | 0.180 |
Why?
| | Weight Reduction Programs | 1 | 2020 | 25 | 0.180 |
Why?
| | Pneumatosis Cystoides Intestinalis | 1 | 2020 | 2 | 0.180 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 19 | 0.180 |
Why?
| | Liver Function Tests | 1 | 2019 | 4 | 0.180 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 11 | 0.170 |
Why?
| | Anticonvulsants | 1 | 2019 | 25 | 0.170 |
Why?
| | Antipsychotic Agents | 1 | 2019 | 14 | 0.170 |
Why?
| | United States | 2 | 2019 | 669 | 0.170 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2011 | 11 | 0.170 |
Why?
| | Graft Survival | 1 | 2019 | 31 | 0.170 |
Why?
| | Incidence | 1 | 2019 | 133 | 0.170 |
Why?
| | Genetic Therapy | 1 | 2019 | 7 | 0.170 |
Why?
| | Ion Channels | 1 | 2019 | 3 | 0.170 |
Why?
| | Ascites | 1 | 2019 | 4 | 0.170 |
Why?
| | Hepatoblastoma | 1 | 2019 | 7 | 0.160 |
Why?
| | Liver Neoplasms | 1 | 2019 | 15 | 0.160 |
Why?
| | Drainage | 1 | 2019 | 36 | 0.160 |
Why?
| | Transplantation Tolerance | 2 | 2010 | 2 | 0.160 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 117 | 0.160 |
Why?
| | Thrombelastography | 1 | 2018 | 2 | 0.160 |
Why?
| | Resuscitation | 1 | 2018 | 6 | 0.160 |
Why?
| | Infant, Premature | 1 | 2019 | 85 | 0.160 |
Why?
| | Blood Transfusion | 1 | 2018 | 13 | 0.150 |
Why?
| | Necrobiotic Xanthogranuloma | 1 | 2018 | 1 | 0.150 |
Why?
| | Dissection | 1 | 2018 | 3 | 0.150 |
Why?
| | Pregnancy | 1 | 2019 | 216 | 0.150 |
Why?
| | Cicatrix | 1 | 2018 | 5 | 0.150 |
Why?
| | Caregivers | 1 | 2018 | 40 | 0.150 |
Why?
| | Skin | 1 | 2018 | 15 | 0.150 |
Why?
| | Pediatric Obesity | 1 | 2020 | 137 | 0.150 |
Why?
| | Glucocorticoids | 1 | 2018 | 32 | 0.150 |
Why?
| | Liver | 2 | 2022 | 126 | 0.150 |
Why?
| | Quality of Life | 1 | 2018 | 140 | 0.140 |
Why?
| | Intestinal Diseases | 2 | 2013 | 4 | 0.140 |
Why?
| | Prognosis | 2 | 2021 | 211 | 0.140 |
Why?
| | Bilirubin | 3 | 2023 | 26 | 0.130 |
Why?
| | Health Resources | 1 | 2015 | 17 | 0.130 |
Why?
| | Pneumonia, Aspiration | 1 | 2015 | 8 | 0.130 |
Why?
| | Mice | 3 | 2011 | 348 | 0.120 |
Why?
| | Genome-Wide Association Study | 1 | 2015 | 190 | 0.120 |
Why?
| | Severity of Illness Index | 2 | 2013 | 149 | 0.120 |
Why?
| | Membrane Glycoproteins | 2 | 2024 | 14 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 28 | 0.120 |
Why?
| | Stem Cell Transplantation | 1 | 2013 | 15 | 0.120 |
Why?
| | Carrier Proteins | 2 | 2024 | 35 | 0.120 |
Why?
| | Graft vs Host Disease | 1 | 2013 | 12 | 0.120 |
Why?
| | Mice, Inbred BALB C | 2 | 2011 | 29 | 0.120 |
Why?
| | Parenteral Nutrition, Total | 1 | 2013 | 6 | 0.110 |
Why?
| | Calcineurin | 1 | 2013 | 1 | 0.110 |
Why?
| | Pancreas Transplantation | 1 | 2013 | 2 | 0.110 |
Why?
| | Anemia, Hemolytic, Autoimmune | 1 | 2013 | 2 | 0.110 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2013 | 5 | 0.110 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2013 | 1 | 0.110 |
Why?
| | Fish Oils | 1 | 2013 | 1 | 0.110 |
Why?
| | Infant, Newborn | 3 | 2023 | 816 | 0.110 |
Why?
| | Apoptosis | 1 | 2012 | 52 | 0.100 |
Why?
| | Portal Vein | 2 | 2023 | 8 | 0.100 |
Why?
| | Lymphocyte Activation | 2 | 2009 | 7 | 0.100 |
Why?
| | Transplantation, Isogeneic | 1 | 2011 | 1 | 0.100 |
Why?
| | Cell Survival | 1 | 2011 | 20 | 0.100 |
Why?
| | Mice, Knockout | 1 | 2011 | 59 | 0.100 |
Why?
| | Body Mass Index | 2 | 2022 | 157 | 0.090 |
Why?
| | Risk Assessment | 2 | 2021 | 137 | 0.090 |
Why?
| | Biopsy | 3 | 2018 | 60 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2021 | 304 | 0.090 |
Why?
| | Metformin | 1 | 2009 | 5 | 0.080 |
Why?
| | Antigen Presentation | 1 | 2009 | 1 | 0.080 |
Why?
| | Immunotherapy, Adoptive | 1 | 2009 | 5 | 0.080 |
Why?
| | Chemotaxis | 1 | 2009 | 6 | 0.080 |
Why?
| | B-Lymphocytes | 1 | 2009 | 24 | 0.080 |
Why?
| | Cytokines | 1 | 2009 | 48 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 55 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2009 | 53 | 0.080 |
Why?
| | Recurrence | 2 | 2019 | 110 | 0.080 |
Why?
| | Signal Transduction | 1 | 2009 | 132 | 0.080 |
Why?
| | Obesity | 1 | 2009 | 125 | 0.080 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2007 | 1 | 0.070 |
Why?
| | Pediatrics | 2 | 2019 | 186 | 0.070 |
Why?
| | Allografts | 2 | 2019 | 7 | 0.070 |
Why?
| | Steroids | 2 | 2019 | 16 | 0.070 |
Why?
| | Disease Progression | 2 | 2019 | 111 | 0.070 |
Why?
| | Thiazepines | 1 | 2024 | 1 | 0.060 |
Why?
| | Methylamines | 1 | 2024 | 2 | 0.060 |
Why?
| | Double-Blind Method | 1 | 2024 | 44 | 0.060 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 3 | 0.060 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 19 | 0.060 |
Why?
| | Parenteral Nutrition | 1 | 2023 | 7 | 0.060 |
Why?
| | Registries | 1 | 2023 | 92 | 0.050 |
Why?
| | Prevalence | 1 | 2023 | 146 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 2022 | 18 | 0.050 |
Why?
| | Immunity, Humoral | 1 | 2022 | 14 | 0.050 |
Why?
| | Aspartate Aminotransferases | 1 | 2022 | 4 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2022 | 10 | 0.050 |
Why?
| | Patient Transfer | 1 | 2022 | 8 | 0.050 |
Why?
| | Antibodies, Viral | 1 | 2022 | 47 | 0.050 |
Why?
| | Vaccination | 1 | 2022 | 71 | 0.050 |
Why?
| | Societies, Medical | 1 | 2022 | 51 | 0.050 |
Why?
| | Secondary Prevention | 1 | 2022 | 7 | 0.050 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2022 | 15 | 0.050 |
Why?
| | Urban Population | 1 | 2022 | 27 | 0.050 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2021 | 1 | 0.050 |
Why?
| | Codon, Nonsense | 1 | 2021 | 6 | 0.050 |
Why?
| | Survival Analysis | 1 | 2021 | 50 | 0.050 |
Why?
| | Rural Population | 1 | 2022 | 42 | 0.050 |
Why?
| | Data Mining | 1 | 2021 | 5 | 0.050 |
Why?
| | Data Collection | 1 | 2021 | 29 | 0.050 |
Why?
| | Aged, 80 and over | 1 | 2021 | 151 | 0.050 |
Why?
| | Ikaros Transcription Factor | 1 | 2020 | 3 | 0.050 |
Why?
| | Databases, Factual | 1 | 2021 | 108 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2020 | 16 | 0.040 |
Why?
| | Age Factors | 1 | 2021 | 210 | 0.040 |
Why?
| | Aged | 1 | 2021 | 378 | 0.040 |
Why?
| | Waiting Lists | 1 | 2019 | 12 | 0.040 |
Why?
| | Risk | 1 | 2019 | 41 | 0.040 |
Why?
| | Tissue and Organ Procurement | 1 | 2019 | 17 | 0.040 |
Why?
| | Patient Preference | 1 | 2019 | 4 | 0.040 |
Why?
| | Algorithms | 1 | 2020 | 105 | 0.040 |
Why?
| | Risk Factors | 1 | 2021 | 487 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2019 | 39 | 0.040 |
Why?
| | Cisplatin | 1 | 2019 | 10 | 0.040 |
Why?
| | Patient Safety | 1 | 2019 | 20 | 0.040 |
Why?
| | Quality Improvement | 1 | 2019 | 60 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 55 | 0.040 |
Why?
| | Kidney Diseases | 1 | 2019 | 71 | 0.040 |
Why?
| | Kidney | 1 | 2019 | 94 | 0.040 |
Why?
| | Glomerular Filtration Rate | 1 | 2019 | 115 | 0.040 |
Why?
| | Plasma | 1 | 2018 | 7 | 0.040 |
Why?
| | Back | 1 | 2018 | 1 | 0.040 |
Why?
| | Abdomen | 1 | 2018 | 12 | 0.040 |
Why?
| | Thigh | 1 | 2018 | 5 | 0.040 |
Why?
| | Parents | 1 | 2019 | 157 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2015 | 22 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2015 | 53 | 0.030 |
Why?
| | Hospital Costs | 1 | 2015 | 29 | 0.030 |
Why?
| | Critical Illness | 1 | 2015 | 22 | 0.030 |
Why?
| | Inpatients | 1 | 2015 | 44 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2015 | 215 | 0.030 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2015 | 38 | 0.030 |
Why?
| | Length of Stay | 1 | 2015 | 233 | 0.030 |
Why?
| | Hospitalization | 1 | 2015 | 210 | 0.030 |
Why?
| | Transaminases | 1 | 2013 | 1 | 0.030 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 1 | 0.030 |
Why?
| | Plasmapheresis | 1 | 2013 | 3 | 0.030 |
Why?
| | Transplantation | 1 | 2013 | 2 | 0.030 |
Why?
| | Hemolysis | 1 | 2013 | 4 | 0.030 |
Why?
| | Everolimus | 1 | 2013 | 2 | 0.030 |
Why?
| | Rituximab | 1 | 2013 | 4 | 0.030 |
Why?
| | Cyclophosphamide | 1 | 2013 | 8 | 0.030 |
Why?
| | Cyclosporine | 1 | 2013 | 6 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2013 | 10 | 0.030 |
Why?
| | Body Height | 1 | 2013 | 34 | 0.030 |
Why?
| | Medical Records | 1 | 2013 | 14 | 0.030 |
Why?
| | Penicillins | 1 | 2013 | 8 | 0.030 |
Why?
| | Nebraska | 1 | 2013 | 2 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2013 | 11 | 0.030 |
Why?
| | Intestinal Volvulus | 1 | 2013 | 11 | 0.030 |
Why?
| | Hyperbilirubinemia | 1 | 2013 | 8 | 0.030 |
Why?
| | Triglycerides | 1 | 2013 | 22 | 0.030 |
Why?
| | Nephrotic Syndrome | 1 | 2013 | 29 | 0.030 |
Why?
| | Gastroschisis | 1 | 2013 | 23 | 0.030 |
Why?
| | Epithelium | 1 | 2012 | 8 | 0.030 |
Why?
| | Observer Variation | 1 | 2012 | 16 | 0.030 |
Why?
| | Time Factors | 1 | 2013 | 250 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2012 | 199 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2010 | 32 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2010 | 84 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2007 | 6 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2007 | 6 | 0.020 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2007 | 6 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 15 | 0.020 |
Why?
| | Up-Regulation | 1 | 2007 | 25 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2007 | 92 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|